ReutersReuters

India's Dr Reddy's up as analysts see growth from generic GLP-1 launch

RefinitivBacaan kurang dari 1 minit

** Indian drugmaker Dr Reddy's Laboratories DRREDDY rise 2.4% to 1,277 rupees

** Co plans to launch a generic version of Novo Nordisk's NOVO_B blockbuster weight-loss drug Wegovy in 87 countries next year

** Co targets early Semaglutide launch in Canada and more than 85 markets ahead of March 2026 expiries

** Jefferies sees Semaglutide as key growth driver;

** Adds, Abatacept IV- an autoimmune drug- launch in January 2027 is also seen boosting growth

** Both products expected to face limited competition and low price erosion- Jefferies

** Jefferies upgrades FY27-28 earnings per share by 10-15% on Semaglutide, Abatacept inclusion

** Co posts narrow Q1 profit miss on U.S. pricing pressure, competition, rev up 11.4% y/y, led by 11% domestic growth

** Goldman Sachs raises its FY26-28 earnings per share view by 3-14%, factors in higher sales in Semaglutide sales in Canada

** YTD, stock down ~10% in 2025 vs a 6.4% rise in Nifty 50 and a 3.8% fall in Nifty pharma index CNXPHARMA

Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini